P/E ratio for Ultragenyx Pharmaceutical (RARE)
P/E ratio as of July 2025 (TTM): -4.70
According to Ultragenyx Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -4.70408. At the end of 2024 the company had a P/E ratio of -6.64.
P/E ratio history for Ultragenyx Pharmaceutical from 2014 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -6.64 | 15.59% |
| 2023 | -5.74 | 25.27% |
| 2022 | -4.58 | -63.43% |
| 2021 | -12.5 | -71.57% |
| 2020 | -44.1 | 634.94% |
| 2019 | -6.00 | -46.19% |
| 2018 | -11.1 | 70.91% |
| 2017 | -6.52 | -42.48% |
| 2016 | -11.3 | |
| 2014 | -18.9 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 BioMarin Pharmaceutical BMRN | 21.2 | -550.13% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | -20.4 | 334.37% | 🇺🇸 USA |
 Esperion Therapeutics ESPR | -1.84 | -60.94% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | -2.10 | -55.40% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.